BioRestorative Therapies (OTC: BRTX) develops therapeutic products primarily using adult stem cells. The company’s lead cell therapy candidate is formulated from autologous cultured mesenchymal stem cells for the non-surgical treatment of chronic lumbar disc disease. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and potentially face the prospect of surgery. BioRestorative Therapies is also developing an allogeneic cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to regulate metabolic homeostasis in humans. For more information, visit the company’s website at www.biorestorative.com